Want to see CLDX full AI Analyst Report?
Top Page
Celldex
(NASDAQ:CLDX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$40.00
▲(13.38% Upside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by weak financial performance (sharp revenue decline, large losses, and substantial cash burn). Offsetting this, technicals are notably positive with the stock trading above major moving averages and positive MACD. Valuation remains constrained by losses (negative P/E), while recent corporate actions improve liquidity but introduce dilution risk.
Positive Factors
Balance Sheet Strength
Very low leverage materially reduces refinancing and interest-rate risk for a cash-burning biotech. That structural balance-sheet strength gives management flexibility to fund clinical programs, pursue partnerships, or withstand trial setbacks without immediate liquidity distress over the next several months.
Negative Factors
Weak Revenue and Large Losses
Steep revenue decline and persistent, large operating losses translate directly into heavy cash burn, limiting internal funding for R&D and commercialization. Structurally, absent approvals or partner milestone payments the company remains dependent on external financing to sustain operations over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low leverage materially reduces refinancing and interest-rate risk for a cash-burning biotech. That structural balance-sheet strength gives management flexibility to fund clinical programs, pursue partnerships, or withstand trial setbacks without immediate liquidity distress over the next several months.
Read all positive factors
Celldex (CLDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.99B
Dividend YieldN/A
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth-88.54%
EPS Growth-58.13%
CountryUS
Employees198
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.27
Shares Outstanding78,492,070
10 Day Avg. Volume933,099
30 Day Avg. Volume1,193,186
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$56.92Price Target Upside61.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.21M
Celldex Business Overview & Revenue Model
Company Description
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both i...
How the Company Makes Money
Celldex is a clinical-stage biotechnology company and, as such, it typically does not generate recurring revenue from marketed products. Its earnings potential and reported revenue, when present, generally come from (a) collaboration and licensing...
Celldex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 820.00K | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Gross Profit | -117.16M | 1.50M | -156.53M | -111.13M | -79.90M | -48.66M |
| EBITDA | -280.32M | -255.42M | -154.69M | -139.03M | -104.20M | -66.08M |
| Net Income | -283.69M | -258.80M | -157.86M | -141.43M | -112.33M | -70.51M |
Balance Sheet | ||||||
| Total Assets | 511.25M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Cash, Cash Equivalents and Short-Term Investments | 451.46M | 518.57M | 725.28M | 421.70M | 304.95M | 408.25M |
| Total Debt | 1.91M | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Total Liabilities | 55.03M | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Stockholders Equity | 456.23M | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
Cash Flow | ||||||
| Free Cash Flow | -225.96M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Operating Cash Flow | -222.16M | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Investing Cash Flow | 238.24M | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Financing Cash Flow | 2.51M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
Celldex Technical Analysis
Positive
35.28
Price Trends
34.62
Positive
33.35
Positive
29.84
Positive
Market Momentum
1.03
Negative
70.56
Negative
91.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 35.28 is below the 20-day moving average (MA) of 37.17, above the 50-day MA of 34.62, and above the 200-day MA of 29.84, indicating a bullish trend. The MACD of 1.03 indicates Negative momentum. The RSI at 70.56 is Negative, neither overbought nor oversold. The STOCH value of 91.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.82B | -4.42 | -50.17% | ― | 34.26% | 23.00% | |
59 Neutral | $2.41B | -6.73 | -76.09% | ― | -58.40% | -31.99% | |
58 Neutral | $2.21B | -14.91 | -44.10% | ― | 1205.52% | 81.79% | |
56 Neutral | $2.99B | -8.91 | -50.72% | ― | -88.54% | -58.13% | |
52 Neutral | $2.58B | -9.52 | -51.15% | ― | -63.29% | 25.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.39B | -8.39 | -87.00% | ― | -36.24% | 11.52% |
* Healthcare Sector Average
CLDX
Celldex
41.06
19.62
91.51%
NKTR
Nektar Therapeutics
73.09
50.64
225.57%
IOVA
Iovance Biotherapeutics
4.34
1.76
68.22%
NRIX
Nurix Therapeutics
25.12
14.66
140.15%
NUVB
Nuvation Bio
6.37
4.02
171.06%
IMNM
Immunome
25.52
15.06
143.98%
Celldex Corporate Events
Business Operations and StrategyShareholder Meetings
Celldex Shareholders Approve Expanded Equity Incentive Plan
Positive
Jun 26, 2026
At its June 25, 2026 annual meeting, Celldex Therapeutics stockholders approved an amendment to the company’s 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifyi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.